AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33960725
Drug: GLPG1205 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1205 250 mg loading dose followed by 50 mg once daily for 13 days (open-label part)
Trial: 32386000
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg orally every night for 4 weeks
Trial: 32386000
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group with atorvastatin and subcutaneous injection of 140 mg evolocumab every 2 weeks for 4 weeks
Trial: 33050910
Drug: SRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT with concurrent systemic therapies (ST) including chemotherapy, immunotherapy, targeted therapy, and hormonotherapy.
Trial: 33050910
Drug: SRT alone
RxNorm normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT alone without concurrent ST.
Trial: 35884990
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo
Trial: 33782086
Drug: Nutritional formulation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional formulation containing myo-inositol, probiotics, and multiple micronutrients (intervention)
Trial: 32169689
Drug: Continued escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued escitalopram treatment
Trial: 35675076
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of atogepant
Trial: 35675076
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of atogepant
Trial: 35675076
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of atogepant
Trial: 35274326
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg plus standard therapy (hydroxychloroquine + Kaletra®)
Trial: 35274326
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (hydroxychloroquine + Kaletra®)
Trial: 37087308
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) algorithm
Trial: 33066811
Drug: Music-based synchronous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music-based synchronous finger tapping (SFT) intervention for 25 minutes daily for 8 weeks
Trial: 34895700
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of relugolix (REL) orally once a day for 24 weeks
Trial: 34895700
Drug: 3.75 or
RxNorm normalized name: Zileze 3.75 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 or 1.88 mg of leuprorelin (LEU) subcutaneously every 4 weeks for 24 weeks
Trial: 34895700
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of relugolix (REL)
Trial: 34895700
Drug: 3.75 or
RxNorm normalized name: Zileze 3.75 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 or 1.88 mg of leuprorelin (LEU)
Trial: 38752352
Drug: Sildenafil 20
RxNorm normalized name: sildenafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 20 mg TID
Trial: 38752352
Drug: Sildenafil 5
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 5 mg TID
Trial: 34028361
Drug: Guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-based cognitive behavioral therapy for insomnia (iCBT-I)
Trial: 34105207
Drug: Anlotinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (12 mg/day; days 1–14; 21 days per cycle)
Trial: 35570513
Drug: Tele-Mindfulness Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-Mindfulness Based Cognitive Therapy (tele-MBCT), 8 weekly live online sessions, average daily practice of 23.58±45.71 minutes.
Trial: 33599270
Drug: Continue on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue on first-line therapy (control)
Trial: 32947459
Drug: Cetaphil Cream,
RxNorm normalized name: Cetaphil Cream, topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetaphil Cream, Aveeno Eczema Therapy Moisturizing Cream, CeraVe Moisturizing Cream, Vaseline (applied to nonlesional skin of one forearm)
Trial: 36086755
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) and electronic moxibustion (EM) cotreatment, 3 times a week for 6 weeks, alongside previously prescribed alpha blocker.
Trial: 36086755
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group continued to use the previously prescribed alpha blocker alone for 6 weeks.
Trial: 33544052
Drug: Operationalization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operationalization of risk perception (susceptibility only, severity only, or combination of the two)
Trial: 35446230
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for generalized anxiety disorder (GAD)
Trial: 32998206
Drug: Magnesium creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium creatine chelate (MgCr‐C) supplementation, 5500 mg (0.07 g/kg/d) in 4 capsules per day
Trial: 32998206
Drug: Placebo (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corn starch in identical 4 capsules)
Trial: 35747502
Drug: Epidermal growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal growth factor receptor-targeted therapy
Trial: 32901962
Drug: Root canal
RxNorm normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Root canal treatment with tissue-level restoration (TL group)
Trial: 32901962
Drug: Root canal
RxNorm normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Root canal treatment with normal occlusal contacts (OC group)
Trial: 32901962
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (healthy patients with root canal treatments)
Trial: 32588401
Drug: Solriamfetol 75
RxNorm normalized name: solriamfetol 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 75 mg
Trial: 35421771
Drug: Constant low-temperature
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant low-temperature cold spray (programme A; n = 47)
Trial: 35421771
Drug: Low-to-normal temperature
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-to-normal temperature spray (programme B; n = 49)
Trial: 35463348
Drug: Reduced-dose chemoradiotherapy
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose chemoradiotherapy (rdCRT) (56 Gy) with weekly carboplatin
Trial: 35307727
Drug: Oral enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enteral nutrition combined with microbial preparations
Trial: 35307727
Drug: Traditional intestinal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional intestinal preparation (control)
Trial: 35535772
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy for Insomnia (ACT‐I)
Trial: 33951124
Drug: oral sulfate
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral sulfate solution (OSS)
Trial: 32306008
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition support in addition to chemotherapy
Trial: 35606883
Drug: Evolocumab (140mg)
RxNorm normalized name: evolocumab 140 MG/ML
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Evolocumab (140mg) administration once within 72 h before CABG
Trial: 35606883
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no administration)
Trial: 35606883
Drug: Evolocumab (140mg)
RxNorm normalized name: evolocumab 140 MG/ML
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Evolocumab (140mg) administration
Trial: 33533487
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MRI and Ki-67
Trial: 34479601
Drug: IFN‐?1a (11?g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐?1a (11?g or 3MIU) injected subcutaneously at day 1, 3, 7, and 10 in addition to standard of care
Trial: 32141389
Drug: Intermittent second-line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent second-line chemotherapy (capecitabine or non-pegylated liposomal doxorubicin, given as two times four cycles)
Trial: 32141389
Drug: Continuous second-line
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous second-line chemotherapy (capecitabine or non-pegylated liposomal doxorubicin, given as eight consecutive cycles)
Trial: 32141389
Drug: Intermittent second-line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent second-line chemotherapy
Trial: 32141389
Drug: Continuous second-line
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous second-line chemotherapy
Trial: 34563875
Drug: Initial hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial hydroxyurea treatment for children with SCA and abnormal transcranial Doppler (TCD) velocities
Trial: 35887829
Drug: Optilyte® infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optilyte® infusion
Trial: 35887829
Drug: Geloplasma® infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geloplasma® infusion
Trial: 33440972
Drug: Sevoflurane inhalation
RxNorm normalized name: Sevoflurane Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane inhalation without propofol infusion (group Sev)
Trial: 33440972
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (group Pro)
Trial: 32144059
Drug: Single-Injection Paravertebral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Injection Paravertebral Block (PVB)
Trial: 32710391
Drug: CT-P13 (biosimilar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 (biosimilar infliximab) given as a single infusion of 5 to 10 mg/kg
Trial: 35907935
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality therapy (VRT) - active content
Trial: 35907935
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality therapy (VRT) - passive content
Trial: 32860031
Drug: Vupanorsen 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vupanorsen 40 mg Q4W
Trial: 32860031
Drug: Vupanorsen 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vupanorsen 80 mg Q4W
Trial: 32860031
Drug: Vupanorsen 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vupanorsen 20 mg QW
Trial: 35076327
Drug: Local oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local oestrogen (oestriol) therapy
Trial: 33099947
Drug: Preoperative neo‐adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative neo‐adjuvant chemotherapy+surgery+postoperative radiotherapy
Trial: 35426318
Drug: Cognitive‐Behavioral Transdiagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐Behavioral Transdiagnostic Therapy (TD‐CBT)
Trial: 32807162
Drug: Cinnamaldehyde (27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamaldehyde (27 μg/mL)
Trial: 35429285
Drug: 101BHG‐D01 nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 101BHG‐D01 nasal spray (40 µg to 960 µg)
Trial: 33141110
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (oxycodone)
Trial: 33141110
Drug: Nurse-administered oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered oral oxycodone
Trial: 34848133
Drug: Riociguat 2.5
RxNorm normalized name: riociguat 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat 2.5 mg three times daily
Trial: 33180322
Drug: LEAP CML-CP
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEAP CML-CP recommended therapy
Trial: 32506943
Drug: Antiphospholipid antibody
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiphospholipid antibody IgG positivity in patients with dysglycaemia
Trial: 35595254
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly factor VIII prophylaxis (10 U/kg)
Trial: 35595254
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly factor VIII prophylaxis (10 U/kg)
Trial: 35595254
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly factor VIII prophylaxis
Trial: 35595254
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly factor VIII prophylaxis
Trial: 33079180
Drug: Leronlimab (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leronlimab (700 mg subcutaneously, repeated after 7 days in 17 of 23 patients)
Trial: 34902549
Drug: ADAPT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADAPT plus treatment as usual (TAU)
Trial: 35862871
Drug: Encorafenib 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib 450 mg once daily plus binimetinib 45 mg twice daily
Trial: 35862871
Drug: Encorafenib 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib 300 mg once daily
Trial: 33522396
Drug: Low fat
RxNorm normalized name: Low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat (LF) meal, 15 g of fat
Trial: 33522396
Drug: Moderate fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate fat (MF) meal, 30 g of fat
Trial: 33522396
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat (HF) meal, 60 g of fat
Trial: 33522396
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat (HF) meal administered twice for reproducibility
Trial: 35135619
Drug: ACTION intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTION intervention (Acceptance and Commitment Therapy) plus treatment as usual
Trial: 36376738
Drug: Spesolimab 600
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab 600 mg every 4 weeks
Trial: 36376738
Drug: Spesolimab 600
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab 600 mg every 4 weeks (sensitivity analysis)
Trial: 34296639
Drug: Neural mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural mobilization (straight leg raising and dorsiflexion with two‐ended slider), administered three times/week for six weeks
Trial: 34296639
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative physical therapy program only
Trial: 36190150
Drug: Piezoelectric implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piezoelectric implant site preparation (PISP)
Trial: 34185551
Drug: Donafenib (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donafenib (0.2 g orally twice daily)
Trial: 34185551
Drug: Sorafenib (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (0.4 g orally twice daily)
Trial: 36347056
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose liposomal amphotericin
Trial: 32728299
Drug: RSV F‐protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV F‐protein nanoparticle vaccine
Trial: 35449064
Drug: COVID‐19 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID‐19 vaccine messaging platforms (4‐min video, one‐page informational flyer, brief scripted face‐to‐face message delivered by an ED physician or nurse) during intervention weeks
Trial: 34389605
Drug: Treat-to-target therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target therapy
Trial: 34590561
Drug: Self-made Qingyuan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-made Qingyuan Shenghua decoction (100 mL in the morning and 100 mL in the evening for 7 days)
Trial: 34982098
Drug: Drug-Eluting Stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Stent (DES) - NOVA intracranial sirolimus-eluting stent system
Trial: 35698100
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy group (arm A)
Trial: 32144133
Drug: gefitinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gefitinib + fulvestrant (G+F)
Trial: 34163193
Drug: Fufang Zhenzhu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang Zhenzhu Tiaozhi capsule (FTZ) with basic treatment
Trial: 36053020
Drug: TRAUMACEM V+
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TRAUMACEM V+ Injectable Bone Cement augmentation
Trial: 33223395
Drug: PRN medication
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRN medication prescribed
Trial: 33223395
Drug: PRN medication
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRN medication administered
Trial: 33223395
Drug: PRN medication
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRN medication administration
Trial: 33223395
Drug: Overall PRN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall PRN prescribing and administration
Trial: 34291992
Drug: Enhanced standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced standard treatment (EST)
Trial: 39581631
Drug: Cenerimod 4
RxNorm normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenerimod 4 mg
Trial: 32483139
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 mcg/kg given 2 minutes before intubation
Trial: 32483139
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 mcg/kg given 1 minute before intubation
Trial: 32483139
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 mcg/kg given 3 minutes before intubation
Trial: 36396519
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg for 14 days once daily
Trial: 35903009
Drug: Fluoxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10 mg)
Trial: 36568722
Drug: Boswellia and
RxNorm normalized name: Menthol, Unspecified Form 7 g in 100 g / Camphor (Synthetic) 6 g in 100 g TOPICAL GEL [Max-Relief with Boswellia and Aloe Vera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia and ginger mixture (Memoral: 360 mg Boswellia and 36 mg ginger)
Trial: 32233251
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (0.5 g diluted in 20 ml normal saline)
Trial: 32829540
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic paste
Trial: 35285940
Drug: Higher BMI
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher BMI in estrogen receptor-positive (ER+) African ancestry patients
Trial: 34019711
Drug: KBP-042 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBP-042 (5, 7.5, 10, 20, 20 (evening), 40 μg)
Trial: 34019711
Drug: KBP-042 (5-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBP-042 (5-40 μg)
Trial: 34293413
Drug: Multicomponent chair-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent chair-based exercise intervention (16 weeks, twice a week, 60 min)
Trial: 32769595
Drug: Epidural Steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural Steroid Injection (ESI)